Corporate
2025.10.17
Announcement: Change in Company Spokesperson
Corporate
2023.09.26
Lumosa's LT1001 Receives Approval from Brunei
Expanding its presence in Southeast Asian market
Corporate
2023.07.26
LT3001 Received Formulation Patent from USPTO
Corporate
2023.05.15
Lumosa’s LT1001 Received First European Approval from Ukraine’s SMDC
Corporate
2023.04.19
First subject for LT3001 Phase 2 trial enrolled in China
Corporate
2023.03.07
Lumosa Therapeutics Announces an Out-License Agreement with Pakistan’s AJM Pharma for LT1001